Search

Displaying results 2151 - 2160 of 4344 in total
  1. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    Linolenic acid and stearic acids are contained in hydrogenated soybean oil, but hydrogenation results in reduced unsaturation in linolenic acid.

  2. Drug

    Thiopental

    go.drugbank.com/drugs/DB00599
    ApprovedInvestigationalVet approvedWithdrawn

    It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold.

  3. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.

  4. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

  5. Drug

    Aminolevulinic acid

    go.drugbank.com/drugs/DB00855
    ApprovedInvestigational

    A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]

  6. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

    Products: CIFEROL® 10MG, LENLI CAPSULES 10MG
  7. Drug

    Lorcaserin

    go.drugbank.com/drugs/DB04871
    ApprovedInvestigationalWithdrawn

    It has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5HT2C receptor may alter body weight by regulating satiety.

  8. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  9. Drug

    Pivampicillin

    go.drugbank.com/drugs/DB01604
    ApprovedWithdrawn

    Pivalate ester analog of ampicillin.

  10. Drug

    Biperiden

    go.drugbank.com/drugs/DB00810
    ApprovedInvestigationalWithdrawn

    It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.